

## DAFTAR PUSTAKA

- Anwar, S.L., Haryono, S.J., Aryandono, T. and Haryana, S.M., 2018. *microRNA: biogenesis, fungsi, dan perannya dalam proses karsinogenesis dan penatalaksanaan kanker*. UGM PRESS.
- Balogh, J., Victor III, D., Asham, E.H., Burroughs, S.G., Boktour, M., Saharia, A., Li, X., Ghobrial, R.M. and Monsour Jr, H.P., 2016. Hepatocellular carcinoma: a review. *Journal of hepatocellular carcinoma*, 3, p.41.
- Brumbaugh, C.D., Kim, H.J., Giovacchini, M. and Pourmand, N., 2011. NanoStriDE: normalization and differential expression analysis of NanoString nCounter data. *BMC bioinformatics*. 12(1), pp.1-4.
- Byass, P., 2014. The global burden of liver disease: a challenge for methods and for public health. *BMC medicine*, 12(1), pp.1-3.
- Cescon, D.W., Bratman, S.V., Chan, S.M. and Siu, L.L., 2020. Circulating tumor DNA and liquid biopsy in oncology. *Nature Cancer*, 1(3), pp.276-290.
- Dhanasekaran, R., Bandoh, S. and Roberts, L.R., 2016. Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances. *F1000Research*, 5.
- FDA-NIH Biomarker Working Group, 2016 BEST (Biomarkers, EndpointS, and other Tools) resource.
- Fitzgerald, T.L. and McQualter, R.B., 2014. The quantitative real-time polymerase chain reaction for the analysis of plant gene expression. In *Cereal Genomics* (pp. 97-115). Humana Press, Totowa, NJ.
- Fornier, A., Gilibert, M., Bruix, J., & Raoul, J. 2014. Treatment of intermediate stage hepatocellular carcinoma. *Nature*.
- Fu, Haiyan; Subramanian, Romesh R.; Masters, Shane C. 2000. *14-3-3 Proteins: Structure, Function, and Regulation*. 40(1), 617647. doi:10.1146/annurev.pharmtox.40.1.617
- Galun, D., Basaric, D., Zuvella, M., Bulajic, P., Bogdanovic, A., Bidzic, N., & Milicevic, M. 2015. Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols. *World Journal of Hepatology*.
- Geong, G.Y., Kang, S.H. and Lee, C.M., 2019. An Updated Review on the Epidemiology, Pathophysiology, Etiology and Diagnosis of Liver Cirrhosis.
- Giacinti, C., & Giordano, A. (2006). RB and cell cycle progression. *Oncogene*. 25(38), 5220-5227.

- GLOBOCAN. 2018. <https://gco.iarc.fr/today/>. Diakses pada 29 Juli 2020
- Gorgannezhad, L., Umer, M., Islam, M.N., Nguyen, N, T., Shiddiky, M.J.A. 2018. Circulating tumor DNA and liquid biopsy: Opportunities, challenges, and recent advances in detection technologies. *Lab Chip*. 18, 1174–1196.
- Gupta, P., Cairns, M. J., dan Saksena, N. K., 2014, “Regulation Of Gene Expression By MicroRNA In HCV Infection and HCV Mediated Hepatocellular Carcinoma”. *Virology Journal*. 11 (64): 1-14.
- Hata, A. and Lieberman, J., 2015. Dysregulation of microRNA biogenesis and gene silencing in cancer. *Sci. Signal.*, 8(368), pp.re3-re3. Huntzinger, E. and Izaurralde, E., 2011. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. *Nature Reviews Genetics*. 12(2), pp.99-110.
- He, L. and Hannon, G.J., 2004. MicroRNAs: small RNAs with a big role in gene regulation. *Nature Reviews Genetics*. 5(7), pp.522-531.
- Huang, W., 2017. MicroRNAs: biomarkers, diagnostics, and therapeutics. In *Bioinformatics in MicroRNA Research* (pp. 57-67). Humana Press, New York, NY.
- Jemal A, Ward EM, Johnson CJ, et al. 2017. Annual Report to the Nation on the Status of Cancer. Featuring Survival. *J Natl Cancer Inst*. 109.
- Jia, S., Zhang, R., Li, Z. and Li, J., 2017. Clinical and biological significance of circulating tumor cells, circulating tumor DNA, and exosomes as biomarkers in colorectal cancer. *Oncotarget*, 8(33), p.55632.
- Johnson, D. G., & Schneider-Broussard, R. 1998. Role of E2F in cell cycle control and cancer. *Front Biosci*. 3, d447-d448.
- Kinoshita, A., Onoda, H., Fushiya, N., Koike, K., Nishino, H., & Tajiri, H. (2015). Staging systems for hepatocellular carcinoma: Current status and future perspectives. *World Journal of Hepatology*.
- Kumar P, Clark M. 2009. Chapter 7: Liver, biliary tract and pancreatic disease. Kumar & Clark’s Clinical Medicine. 7th Edition. Elsevier Limited. Spain, 345-47, 2009.
- Liu, A.M., Wang, W. and Luk, J.M., 2014. miRNAs: new tools for molecular classification, diagnosis and prognosis of hepatocellular carcinoma. *Hepatic oncology*, 1(3), pp.323-329.

- Ma, L., 2014. Pathology Features and Molecular Genetic Mechanisms of Hepatocellular Carcinoma Development in Patients with Hepatitis C Associated Liver Cirrhosis. *Hereditary Genetics: Current Research*, 3(2).
- Marrugo-Ramírez, J., Mir, M. and Samitier, J., 2018. Blood-based cancer biomarkers in liquid biopsy: a promising non-invasive alternative to tissue biopsy. *International journal of molecular sciences*, 19(10), p.2877.
- Martin, K.J., Fournier, M.V., Reddy, G.P.V. and Pardee, A.B., 2010. A need for basic research on fluid-based early detection biomarkers. *Cancer research*, 70(13), pp.5203-5206.
- Maulidia V N R., Wardhani P., Setyoboedi B., 2020. AST, ALT and Albumin Level in Chronic Hepatitis B Patients with and without Complications of Cirrhosis and Hepatocellular Carcinoma. *Indonesian Journal of Clinical Pathology and Medical Laboratory*. 26 (3): 344 – 349.
- Mazzanti, R., Arena, U. and Tassi, R., 2016. Hepatocellular carcinoma: Where are we?. *World journal of experimental medicine*, 6(1), p.21.
- Mehlich, Dawid; Garbicz, Filip; Włodarski, Paweł K. (2018). The emerging roles of the polycistronic miR-106b~25 cluster in cancer a comprehensive review. *Biomedicine & Pharmacotherapy*. 107. 1183 1195.
- Molania, R., Gagnon-Bartsch, J.A., Dobrovic, A. and Speed, T.P., 2019. A new normalization for Nanostring nCounter gene expression data. *Nucleic acids research*, 47(12), pp.6073-6083.
- NanoString Technologies, Inc. Total RNA and Cell Lysate Protocols. nCounter™ Gene Expression Assay Manual. 2009.
- Nanostring Technologies. 2012. “nCounter® Analysis System” [http://www.biosystems.com.ar/archivos/folletos/165/PDS\\_nCounter\\_System.pdf](http://www.biosystems.com.ar/archivos/folletos/165/PDS_nCounter_System.pdf). Diakses pada 10 September 2020.
- Oyagbemi, A. A., Azeez, O. I., & Saba, A. B. 2010. Hepatocellular carcinoma and the underlying mechanisms. *African Health Sciences*, 10 (1), 93–8.
- Qi, P., Cheng, S.Q., Wang, H., Li, N., Chen, Y.F. and Gao, C.F., 2011. Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. *PloS one*, 6(12), p.e28486.
- Ramalho, M., Matos, A.P., AlObaidy, M., Velloni, F., Altun, E. and Semelka, R.C., 2017. Magnetic resonance imaging of the cirrhotic liver: diagnosis of hepatocellular carcinoma and evaluation of response to treatment-Part 1. *Radiologia brasileira*, 50(1), pp.38-47.

- Razumilava, N., Bronk, S.F., Smoot, R.L., Fingas, C.D., Werneburg, N.W., Roberts, L.R. and Mott, J.L., 2012. miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma. *Hepatology*, 55(2), pp.465-475.
- Robertson, E.G., Baxter, G. 2011. Tumour seeding following percutaneous needle biopsy: The real story! *Clin. Radiol.* 66. 1007–1014.
- Sarin, et al., 2016. Asian Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. *Hepatol Int.* 10:1-98.
- Schmittgen, T.D. and Livak, K.J., 2008. Analyzing real-time PCR data by the comparative C T method. *Nature protocols*, 3(6), p.1101.
- Schuppan, D. and Afdhal, N.H., 2008. Liver cirrhosis. *The Lancet*, 371(9615), pp.838-851.
- Sun, J., Lu, H., Wang, X. and Jin, H., 2013. MicroRNAs in hepatocellular carcinoma: regulation, function, and clinical implications. *The Scientific World Journal*, 2013.
- Suryamin, 2013. “NILAI TITIK POTONG ALPHA-1 ACID GLYCOPROTEIN (AAG) SEBAGAI BIOMARKER DIAGNOSTIK KARSINOMA HEPATOSELULAR DENGAN SIROSIS HATI”. Tesis. Fakultas Kedokteran Universitas Indonesia. Jakarta.
- Suva, M.A., 2014. A Brief Review on Liver Cirrhosis: Epidemiology, Etiology, Pathophysiology, Symptoms, Diagnosis and Its Management. *Inventi Rapid: Molecular Pharmacology*.
- Suzuki, H.I., Matsuyama, H., Noguchi, M., Yao, T., Komatsu, N., Mano, H., Sugimoto, K. and Miyazono, K., 2013. Computational dissection of distinct microRNA activity signatures associated with peripheral T cell lymphoma subtypes. *Leukemia*, 27(10), pp.2107-2111.
- Szabo, G. and Bala, S., 2013. MicroRNAs in liver disease. *Nature reviews Gastroenterology & hepatology*. 10(9), p.542.
- Tsochatzis, E.A., Bosch, J. and Burroughs, A.K., 2014. Liver cirrhosis. *The Lancet*. 383(9930), pp.1749-1761.
- Uniprot. 2021. <https://www.uniprot.org/uniprot/Q04917>. Diakses pada tanggal 07 Maret 2021.
- Wang, C., Wang, X., Su, Z., Fei, H., Liu, X. and Pan, Q., 2015. MiR-25 promotes hepatocellular carcinoma cell growth, migration and invasion by inhibiting RhoGDI1. *Oncotarget*, 6(34), p.36231.

- Wang, H., Horbinski, C., Wu, H., Liu, Y., Sheng, S., Liu, J., Weiss, H., Stromberg, A.J. and Wang, C., 2016. NanoStringDiff: a novel statistical method for differential expression analysis based on NanoString nCounter data. *Nucleic acids research*, 44(20), pp.e151-e151.
- Wargasetia, T.L., 2016. The potential of MiRNAs as biomarkers and therapy targets for cancer. *Journal of medicine and health*, 1(3).
- Wu, Yunyu; Zhang, Yan; Wang, Feng; Ni, Qingfeng; Li, Mei (2020). MiR-660-5p promotes the progression of hepatocellular carcinoma by interaction with YWHAH via PI3K/Akt signaling pathway. *Biochemical and Biophysical Research Communications*. 531(4), 480–489. doi:10.1016/j.bbrc.2020.07.034
- Zhang L., Yang L, A-Man X., Huan Z W. 2019. The prognostic significance of serum gamma-glutamyltransferase levels and AST/ ALT in primary hepatic carcinoma. *BMC Cancer*. 19:841.
- Zhang, J., Chen, G., Zhang, P., Zhang, J., Li, X., Gan, D.N., Cao, X., Han, M., Du, H. and Ye, Y.A., 2020. The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis. *PloS one*, 15(2), p.e0228857.
- Zhu, Y., Gu, J., Li, Y., Peng, C., Shi, M., Wang, X., & Chen, H. (2018). MiR-17-5p enhances pancreatic cancer proliferation by altering cell cycle profiles via disruption of RBL2/E2F4-repressing complexes. *Cancer letters*, 412, 59-68.